Mohamed Ismail Abdul Aziz

8PUBLICATIONS
14CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Pharmaceutical delivery technologiesEpidemiological modellingMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Dec 27, 2023
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.

Boon Piang Cher, Sharon Goh, Mohamed Ismail Abdul Aziz

|Dec 14, 2021
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.

Xin Yi Wong, Wee Joo Chng, Mohamed Ismail Abdul Aziz

|Oct 21, 2020
Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore.

Lydia Loke, Soo-Chin Lee, Fiona Pearce

|Oct 15, 2020
Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore.

Ling Eng Tan, Wan Hui Gloria Tan, Mohamed Ismail Abdul Aziz

|Sep 04, 2020
Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.

Mohamed Ismail Abdul Aziz, Wayne Yong Xiang Foo, Chee Keong Toh

|Aug 12, 2020
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective.

Boon Piang Cher, Kar Yee Gan, Mohamed Ismail Abdul Aziz

Pageof 2

Frequent Collaborators

2 joint publications

Ling Eng Tan

2 joint publications

Wan Hui Gloria Tan

2 joint publications

Lydia Pui Yee Loke

2 joint publications

Boon Piang Cher